Objective: The purpose of this study is to observe the short-term brain metabolic network characteristics of Parkinson’s disease patients after STN DBS treatment through PET-CT brain metabolism network analysis.

Background: In recent years, DBS technology has been continuously developed and improved, and multiple studies have shown that DBS treatment can significantly improve symptoms such as limb tremor, motor delay, muscle tone, and non motor symptoms in PD patients, with sustained good effects [5-8].

Method: PD patients who received bilateral subthalamic nucleus DBS treatment in our hospital and met the clinical diagnostic criteria of PD of the International Association for Movement Disorders were enrolled and completed at least one postoperative follow-up, including postoperative 1 year, postoperative 18F-FDG PET imaging examination and clinical evaluation after 3 years and 5 years after operation.

Results: SPM analysis showed that the representative area of ​​reduced glucose metabolism was obtained with the globus pallidus/putamen coordinates as the center, and its relative glucose metabolic value. The difference between before and after treatment in PD patients was statistically significant (P<0.01); the representative area of ​​increased glucose metabolism: centered on the occipital lobe, and the difference was statistically significant (P<0.01).

Compared with the PDRP expression value of 3.62±1.67 at baseline, it was 1.33±1.35 at 1 year after operation, 3.32±1.84 at 3 years after operation and 3.51±2.09 at 5 years after operation, and there was a statistical difference between the groups (P<0.01), There was a significant correlation between the expression value of PDRP and the motor function score (r=0.5723, P=0.0025).

Conclusion: After DBS treatment, the PDRP value significantly decreases, indicating that the thalamic basal ganglia DBS may have a short-term corrective effect on PDRP. However, as the disease progresses, the PDRP value gradually increases, implying that the corrective effect of STN DBS may not be sustainable. This means that although the PDRP analysis method can monitor the changes in PD disease, it may not be a reliable predictor of therapeutic efficacy.

In summary, the results indicate that investigating the aforementioned brain metabolic network indicators within the brain metabolic networks for therapeutic efficacy prediction will be the focus of our research.

FIG2

FIG3

FIG4

Fig 1

References: [1] von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe[J]. Eur Neuropsychopharmacol, 2005,15(4):473-490.
[2] Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2019, 18(5):459-480.

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/metabolic-characteristics-of-brain-network-in-patients-with-parkinsons-disease-after-deep-brain-stimulation/